MA43160B1 - Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique - Google Patents
Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutiqueInfo
- Publication number
- MA43160B1 MA43160B1 MA43160A MA43160A MA43160B1 MA 43160 B1 MA43160 B1 MA 43160B1 MA 43160 A MA43160 A MA 43160A MA 43160 A MA43160 A MA 43160A MA 43160 B1 MA43160 B1 MA 43160B1
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- preparation
- therapeutic application
- cryptophycin compounds
- new cryptophycin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Bedding Items (AREA)
Abstract
La présente invention concerne des composés de cryptophycine de formule (i). L'invention concerne également les charges utiles de cryptophycine, les conjugués de cryptophycine, les compositions les contenant et leur utilisation thérapeutique, notamment comme agents anticancéreux. L'invention concerne également le procédé de préparation de ces conjugués.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306751 | 2015-11-05 | ||
| PCT/EP2016/076603 WO2017076998A1 (fr) | 2015-11-05 | 2016-11-03 | Nouveaux composés et conjugués de cryptophycine, leur préparation et leur utilisation thérapeutique |
| EP16791017.3A EP3371179B1 (fr) | 2015-11-05 | 2016-11-03 | Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43160B1 true MA43160B1 (fr) | 2019-12-31 |
Family
ID=54476881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43160A MA43160B1 (fr) | 2015-11-05 | 2016-11-03 | Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10941139B2 (fr) |
| EP (1) | EP3371179B1 (fr) |
| JP (1) | JP6929292B2 (fr) |
| KR (1) | KR102822076B1 (fr) |
| CN (1) | CN108349960B (fr) |
| AR (1) | AR106604A1 (fr) |
| AU (1) | AU2016347724B2 (fr) |
| CA (1) | CA3003085A1 (fr) |
| CL (1) | CL2018001210A1 (fr) |
| CO (1) | CO2018004581A2 (fr) |
| CR (1) | CR20180256A (fr) |
| CY (1) | CY1122441T1 (fr) |
| DK (1) | DK3371179T3 (fr) |
| EA (1) | EA035625B1 (fr) |
| EC (1) | ECSP18034035A (fr) |
| ES (1) | ES2755101T3 (fr) |
| HK (1) | HK1256754B (fr) |
| HR (1) | HRP20191729T1 (fr) |
| HU (1) | HUE046033T2 (fr) |
| IL (1) | IL259067B (fr) |
| LT (1) | LT3371179T (fr) |
| MA (1) | MA43160B1 (fr) |
| MX (1) | MX374535B (fr) |
| MY (1) | MY189448A (fr) |
| PH (1) | PH12018500852B1 (fr) |
| PL (1) | PL3371179T3 (fr) |
| PT (1) | PT3371179T (fr) |
| RS (1) | RS59498B1 (fr) |
| SG (1) | SG11201803181SA (fr) |
| SI (1) | SI3371179T1 (fr) |
| TN (1) | TN2018000131A1 (fr) |
| TW (1) | TWI714661B (fr) |
| UY (1) | UY36979A (fr) |
| WO (1) | WO2017076998A1 (fr) |
| ZA (1) | ZA201802322B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| TN2019000303A1 (en) * | 2017-05-10 | 2021-05-07 | Sanofi Sa | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
| CN108107103B (zh) * | 2017-12-14 | 2020-10-16 | 华中师范大学 | 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法 |
| ES2988904T3 (es) | 2019-03-07 | 2024-11-22 | Nobo Medicine Inc | Inhibidores de caspasa y métodos de utilización de los mismos |
| US11530204B2 (en) | 2019-09-30 | 2022-12-20 | The Regents Of The University Of Michigan | Biocatalytic synthesis of cryptophycin anticancer agents |
| EP4046996A1 (fr) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Composés de cryptophycine et leurs conjugués |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| EP4495105A1 (fr) | 2023-07-17 | 2025-01-22 | Basf Se | Dérivés d'ester, amide et nitrile d'acide propanoïque de 3-(4-hydroxybut-2-ynoxy) en tant qu'agents de protection contre la corrosion |
| EP4495108A1 (fr) | 2023-07-17 | 2025-01-22 | Basf Se | Dérivés d'acide propanoïque de 3-[2-(2-oxo-1,3-dioxolan-4-ylidene)ethoxy] en tant que précurseurs de monomers dans de polymerisations |
| WO2025082990A1 (fr) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Conjugués anticorps-médicament utilisant deux types différents d'inhibiteurs de topo-isomérase i |
| WO2026013234A1 (fr) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Conjugués anticorps-médicament à triple charge utile (adcs) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09510436A (ja) * | 1993-12-21 | 1997-10-21 | ユニバーシティー オブ ハワイ | 新規なクリプトフィシン類 |
| US20020128185A1 (en) * | 1998-02-25 | 2002-09-12 | Chuan Shih | Pharmaceutical compounds |
| US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| US8212083B2 (en) | 2006-04-27 | 2012-07-03 | Intezyne Technologies, Inc. | Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| UY32914A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| TWI714661B (zh) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | 新穎念珠藻素化合物及接合物、其製備與其治療用途 |
-
2016
- 2016-11-02 TW TW105135522A patent/TWI714661B/zh active
- 2016-11-03 WO PCT/EP2016/076603 patent/WO2017076998A1/fr not_active Ceased
- 2016-11-03 US US15/768,792 patent/US10941139B2/en active Active
- 2016-11-03 MY MYPI2018701424A patent/MY189448A/en unknown
- 2016-11-03 EP EP16791017.3A patent/EP3371179B1/fr active Active
- 2016-11-03 TN TNP/2018/000131A patent/TN2018000131A1/en unknown
- 2016-11-03 JP JP2018541548A patent/JP6929292B2/ja active Active
- 2016-11-03 PT PT167910173T patent/PT3371179T/pt unknown
- 2016-11-03 ES ES16791017T patent/ES2755101T3/es active Active
- 2016-11-03 EA EA201890898A patent/EA035625B1/ru not_active IP Right Cessation
- 2016-11-03 CR CR20180256A patent/CR20180256A/es unknown
- 2016-11-03 HU HUE16791017A patent/HUE046033T2/hu unknown
- 2016-11-03 MA MA43160A patent/MA43160B1/fr unknown
- 2016-11-03 PL PL16791017T patent/PL3371179T3/pl unknown
- 2016-11-03 SI SI201630418T patent/SI3371179T1/sl unknown
- 2016-11-03 HR HRP20191729 patent/HRP20191729T1/hr unknown
- 2016-11-03 HK HK18115834.8A patent/HK1256754B/en unknown
- 2016-11-03 CN CN201680064372.8A patent/CN108349960B/zh active Active
- 2016-11-03 CA CA3003085A patent/CA3003085A1/fr active Pending
- 2016-11-03 MX MX2018005379A patent/MX374535B/es active IP Right Grant
- 2016-11-03 RS RS20191429A patent/RS59498B1/sr unknown
- 2016-11-03 KR KR1020187015447A patent/KR102822076B1/ko active Active
- 2016-11-03 LT LT16791017T patent/LT3371179T/lt unknown
- 2016-11-03 SG SG11201803181SA patent/SG11201803181SA/en unknown
- 2016-11-03 AU AU2016347724A patent/AU2016347724B2/en active Active
- 2016-11-03 DK DK16791017T patent/DK3371179T3/da active
- 2016-11-04 UY UY0001036979A patent/UY36979A/es not_active Application Discontinuation
- 2016-11-04 AR ARP160103379A patent/AR106604A1/es not_active Application Discontinuation
-
2018
- 2018-04-10 ZA ZA2018/02322A patent/ZA201802322B/en unknown
- 2018-04-20 PH PH12018500852A patent/PH12018500852B1/en unknown
- 2018-04-27 CO CONC2018/0004581A patent/CO2018004581A2/es unknown
- 2018-05-01 IL IL259067A patent/IL259067B/en unknown
- 2018-05-03 EC ECIEPI201834035A patent/ECSP18034035A/es unknown
- 2018-05-04 CL CL2018001210A patent/CL2018001210A1/es unknown
-
2019
- 2019-11-06 CY CY20191101166T patent/CY1122441T1/el unknown
-
2020
- 2020-12-10 US US17/118,204 patent/US20210163458A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43160B1 (fr) | Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique | |
| MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MD4584B1 (ro) | (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| GB2511685A (en) | Muscarinic m1 receptor agonists | |
| TR201905009T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. | |
| MA33670B1 (fr) | Derives de pyrrolo[2,3-d]pyrimidine | |
| MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
| EA200971074A1 (ru) | Антивирусные соединения | |
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| MA45222B1 (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MX2013003635A (es) | Compuestos de n-heteroarilo. | |
| EA202090448A1 (ru) | Дигидрооксадиазиноны | |
| MA38803A1 (fr) | Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA33679B1 (fr) | Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| MA35305B1 (fr) | Nouveaux acides pipéridinylmonocarboxyliques à titre d'agonistes des récepteurs de s1p1 | |
| MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
| FR2968662B1 (fr) | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation | |
| MA37999B1 (fr) | Dérivés de macrolide, leur préparation et leur utilisation thérapeutique |